Novolyze intensifies its growth momentum Novolyze

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
226
Novolyze intensifies its growth momentum

Novolyze experienced a significant growth in 2016, notably due to the successful launch of SurroNov dry, ready-to-use surrogates for use during in-plant preventive control validation studies. Novolyze's range of SurroNov surrogates are developed and commercially manufactured to replicate the inactivation of foodborne pathogens such as Salmonella , Listeria monocytogenes , Cronobacter sakazakii and E. coli. The commercialization of this range of innovative surrogate microorganisms has led to significant contracts with leading  food industry manufacturers who recognize they are able to perform in-plant preventive control validations quicker and more efficiently by using SurroNov surrogates.

Bullish growth is strongly driven by the enforcement of new international food safety regulations, including US FDA Food Safety Modernization Act (FSMA). Novolyze's portfolio of products and services provides food safety professionals with cutting-edge solutions to comply with major provisions of these new regulations, including FSMA's requirement to validate the efficacy of preventive controls for microbial hazards of concern.

Novolyze 2016 Highlights:

-Global launch of SurroNov range of surrogate microorganisms and NovoConsult range of process validation services

-Strong investments, including the opening of Novolyze's new R&D facilities, and deployment the NovoGate technological platform

-Intensification of Novolyze's presence in the US

Novolyze announced they will keep investing in 2017 to bring new innovative solutions to their partners. The company plans to release new strains of surrogate microorganisms and diversify its activities to cover a broader perimeter of food products and preventive controls. Novolyze also announced the commercial launch of a new connected service, ValidationOnDemand (VOD). VOD improves the daily verification of industrial preventive controls. The main feature is real-time analysis of time and temperature processing parameters validated using SurroNov surrogate microorganisms.

Karim-Franck Khinouche, CEO of Novolyze remarks, "The commercial launch of SurroNov range of surrogates in 2016 has been very successful and based on industry feedback we are confident that we will also reach our 2017 objectives. Our talented team will continue to imagine and develop innovative services and inspired ways of doing business in order to uphold our commitment of bringing new food safety solutions to the industry. Additionally, in early 2017, we plan to open Novolyze's capital with a fundraising campaign of several million dollars."

About Novolyze:  Novolyze is a food biotechnology company offering a portfolio of products and services to help the food industry comply with major international Food Safety regulations, such as the Food Safety Modernization Act (FSMA) in the US. Novolyze's research has mainly focused on evaluating the inactivation kinetics of foodborne pathogens and identifying suitable surrogate microorganisms to help the food industry perform in-plant Process Challenge Tests. Novolyze surrogate microorganisms are presented in the form of a dry and ready-to-use powder. They can be safely used in-plant to validate the efficacy of a process on the destruction of pathogens. Novolyze currently has offices in the US (Cambridge, MA) and in Europe (Dijon, France).

Karim-Franck KHINOUCHE - Président T (France) : +33 695 285 122 kf@novolyze.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Two Xinjiang Histories Arrive With a Clear State Lens

Updated Category News Views 162

Dusty chronology rarely carries this much present-day weight. Two books released in Beijing on September 2, The History of China's Xinjiang Region and The Religious History in China's Xinjiang Region, are presented as the most comprehensive works on the subject yet produced by Chinese scholars. That is a sizable claim, and it deserves to be read with both attention and a...

Continue Reading
BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 80

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 0

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
TD Pledges $2 Billion to Financial Strength by 2036

Updated Category News Views 83

A Longer-Term Bet on Household Resilience A bank’s community budget rarely grabs the market by the collar, but TD’s new target deserves more than a polite nod. The bank says it will direct $2 billion, or US$1.4 billion, toward helping people build financial strength across North America over the next decade. That is a sizable commitment, even for an institution with...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 59

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 19

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 119

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading
Clickstop's Urbana Expansion Bets on Durable Demand

Updated Category News Views 126

A patch of turned Iowa dirt can say plenty about a company’s nerve. Clickstop broke ground in Urbana on Nov. 19, 2026, for a 43,000-square-foot building, and the message is pretty plain: management believes its recent growth has legs. For a privately held, employee-owned operator serving trucking, construction, lifting and rigging, that is not a casual decision....

Continue Reading
Sleep Number’s Couples Pitch Has Some Fine Print Too

Updated Category News Views 40

A thermostat war in the bedroom is a lousy reason to buy the wrong mattress. Yet that is the mundane, very real problem Sleep Number is leaning into after Expert Consumers named it a leading 2026 choice for couples seeking personalized sleep comfort. The company’s argument is straightforward: two people sharing a bed should not have to share one firmness setting, or...

Continue Reading
Cloud Optical Demand Is Running Ahead of Supply in 2026

Updated Category News Views 20

Fiber capacity has become the awkward bottleneck nobody can wish away. Dell’Oro Group says the optical transport equipment market expanded 24% year over year in the third quarter of 2026, with large North American cloud providers doing the heavy lifting. More pointedly, optical vendor revenue tied to those cloud customers jumped 75%. That is not a gentle improvement in...

Continue Reading

Top 5 Most Recently Viewed Articles

Raphael Bostic's Forecast for Interest Rate Cuts in 2024

Updated Category News Views 139

Fed's Bostic Discusses Future Interest Rate Cuts Atlanta Federal Reserve President Raphael Bostic has recently shared his insights regarding future interest rate adjustments. At a recent event in Atlanta, Bostic indicated that he has projected a further interest rate decrease of 25 basis points this year. This update follows his review of the central bank's recent...

Continue Reading
Boardwalktech Software to Showcase Innovations at Upcoming Event

Updated Category News Views 169

Boardwalktech Software Demonstrates Commitment to Innovation Boardwalktech Software Corp. (TSXV: BWLK) (OTCQB: BWLKF), recognized as a leader in the Intelligent Information Platform sector, has announced that their CEO and Chairman, Andrew Duncan, is set to present at the highly anticipated Planet MicroCap Showcase. This event, in partnership with MicroCapClub, serves as...

Continue Reading
Michael Saylor Advocates for U.S. Leadership in Cryptocurrency

Updated Category News Views 123

Michael Saylor's Vision for Digital Assets Michael Saylor, the co-founder of Strategy Inc. and a prominent advocate for Bitcoin, recently held discussions with key figures in the House Financial Services Committee. His conversations focused on strategies to position the United States as a leading authority in the world of Bitcoin and cryptocurrencies. The Digital Assets...

Continue Reading
Gents Doctor Unveils Insights on Testosterone Therapy and Health

Updated Category News Views 297

Gents Doctor Shares New Insights on Testosterone Therapy Gents Doctor, a well-known male health clinic led by Dr. Majid Sabour, MD, has recently unveiled two important blog posts that explore significant topics related to Testosterone Replacement Therapy (TRT). These posts are designed to inform men who are interested in improving their health through hormone...

Continue Reading
Promising Results from Phase III POLARIS-1 Study of Olverembatinib

Updated Category News Views 233

Exciting Developments in the Treatment of Ph+ ALL At the recent American Society of Hematology (ASH) meeting, cutting-edge research on Olverembatinib, a promising drug from Ascentage Pharma, highlighted its impressive efficacy for patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The findings from the Phase III...

Continue Reading